GRM5 and central nervous system cancer: For example, mGluRs have been heavily reported in neuroblastoma and gliomas [89], with mGluR5 particularly driving tumorigenesis as its inhibition has shown to facilitate hypoxia-induced cell death in gliomas [90], and GIRKs are highly expressed in over 70% of non-small cell lung cancer patients which correlates with more aggressive tumors [91].